A Phase 2 interventional study of JDQ443 in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 45 sites in 19 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Lung Neoplasms by Novartis — 2 open to participants now, 5 under way, none of them phase 3. Lung Neoplasms · Novartis.
Among the 40 studies in Lung Neoplasms by Novartis, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2022, is one of 14 in phase 2, and was the 37th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →2 of the 40 studies in Lung Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 12 more countries
Ages 18–100
By country, each count listing its studies:
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 16 · Phase 3 5 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 95 across the 36 interventional studies, 770 across the 2 observational. Of the 31 that completed or were terminated, 13 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Lung Neoplasms by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Lung Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and have a PD-L1 expression \< 1% (cohort A) or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).
This is a non-randomized, open-label, single-arm, multicenter, phase II study evaluating the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic KRAS G12C-mutated NSCLC.
The study will have 2 non-comparative cohorts that will recruit participants in parallel according to the following characteristics:
The study treatment begins on Cycle 1 Day 1 (C1D1) with the first administration of JDQ443. One treatment cycle consists of 21 (±3) days.
Study completion is defined as the earliest occurrence of one of the following:
Key Inclusion criteria
Presence of a KRAS G12C mutation (all participants) and:
Key Exclusion criteria
Other inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants whose tumors harbor a KRAS G12C mutation and a PD-L1 expression \< 1%, regardless of STK11 mutation status.
Drug: JDQ443
Participants whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥ 1% and an STK11 co-mutation.
Drug: JDQ443
JDQ443 per os (PO) 200 mg twice a day continuously
Overall Response Rate (ORR) as Determined by the Investigator in Cohort A
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort A.
Time frame: Up to approximately 22 months
Key Secondary Outcome Measure: Overall Response Rate (ORR) as Determined by the Investigator in Cohort B
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort B.
Time frame: Up to approximately 22 months
Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs) and Serious Adverse Event (TESAEs), through the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent Adverse Events (TEAEs) in this study are defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose of study treatment, or events that are present prior to the first dose of treatment and increase in severity based on preferred term within 30 days after the last study treatment.
Time frame: Up to approximately 59 months
Plasma JDQ443 Concentration in All Participants
JDQ443 concentration data of all participants were reported separately for each of the two cohorts and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Plasma JDQ443 Concentration in Chinese Participants
JDQ443 concentration data of Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Plasma JDQ443 Concentration in Non-Chinese Participants
JDQ443 concentration data of non-Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Observed Maximum Plasma Concentration (Cmax) of JDQ443
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Cmax was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Time to Reach Maximum Plasma Concentration (Tmax) of JDQ443
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tmax was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Time to Last Nonzero Plasma Concentration (Tlast) of JDQ443
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tlast was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of JDQ443
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUC∞ was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of JDQ443
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUClast was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) of JDQ443
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUCτ was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Total Body Clearance (CL/F) of JDQ443 in Plasma
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. CL/F was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
The study is conducted globally across 19 countries.
| Milestone | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| Started | 72 | 23 |
| Pharmacokinetic analysis set (pas) | 69 | 23 |
| Full pharmacokinetic analysis set (fpas) | 14 | 9 |
| Treatment ongoing | 25 | 5 |
| Discontinued from treatment and continued in the follow-up period | 32 | 10 |
| Discontinued from treatment and did not enter the follow-up period | 15 | 8 |
| Completed | 0 | 0 |
| Not completed | 72 | 23 |
| Withdrew: Treatment ongoing at the time of the data cut-off date 04nov2024 | 25 | 5 |
| Withdrew: Progressive disease | 17 | 9 |
| Withdrew: Physician decision | 16 | 4 |
| Withdrew: Death | 6 | 3 |
| Withdrew: Subject decision | 6 | 2 |
| Withdrew: Adverse event | 2 | 0 |
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort A.
| Percentage (%) of participants | Cohort A- PD-L1<1% |
|---|---|
| Overall Response Rate (ORR) as Determined by the Investigator in Cohort A | 29.2 (19.0 to 41.1) |
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort B.
| Percentage (%) of participants | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|
| Key Secondary Outcome Measure: Overall Response Rate (ORR) as Determined by the Investigator in Cohort B | 21.7 (7.5 to 43.7) |
The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs) and Serious Adverse Event (TESAEs), through the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent Adverse Events (TEAEs) in this study are defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose of study treatment, or events that are present prior to the first dose of treatment and increase in severity based on preferred term within 30 days after the last study treatment.
Results for this outcome have not been posted.
JDQ443 concentration data of all participants were reported separately for each of the two cohorts and summarized using descriptive statistics.
| ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| Cycle 1 Day 1 (predose/0hour) | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 1 (4 hours) | 3170 ± 80.8 | 4980 ± 59.8 |
| Cycle 1 Day 1 (6 hours) | 2970 ± 65.6 | 4190 ± 65.7 |
| Cycle 1 Day 15 (predose/0hour) | 1580 ± 96.8 | 1490 ± 97.5 |
| Cycle 1 Day 15 (1 hour) | 2440 ± 102.0 | 3390 ± 89.3 |
| Cycle 1 Day 15 (2 hours) | 3290 ± 82.7 | 4700 ± 81.8 |
| Cycle 1 Day 15 (3 hours) | 3770 ± 70.4 | 5540 ± 41.7 |
| Cycle 1 Day 15 (4 hours) | 3290 ± 61.0 | 4330 ± 54.5 |
| Cycle 1 Day 15 (6 hours) | 2810 ± 69.7 | 3600 ± 59.9 |
| Cycle 1 Day 15 (8 hours) | 2260 ± 92.9 | 3120 ± 55.4 |
| Cycle 1 Day 15 (12 hours) | 1780 ± 120.5 | 2380 ± 72.7 |
| Cycle 3 Day 1 (predose/0hour) | 1060 ± 160.9 | 1090 ± 178.0 |
| Cycle 5 Day 1 (predose/0hour) | 1000 ± 73.6 | 1320 ± 118.4 |
| Cycle 7 Day 1 (predose/0hour) | 948 ± 74.2 | 1400 ± 99.4 |
JDQ443 concentration data of Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.
| ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| Cycle 1 Day 1 (predose/0hour) | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 1 (4 hours) | 3480 ± 41.1 | 2890 ± 110.9 |
| Cycle 1 Day 1 (6 hours) | 3220 ± 26.7 | 2730 ± 92.7 |
| Cycle 1 Day 15 (predose/0hour) | 1670 ± 95.7 | 1410 ± 113.8 |
| Cycle 1 Day 15 (1 hour) | 2650 ± 164.1 | 1470 ± 249.7 |
| Cycle 1 Day 15 (2 hours) | 3400 ± 92.3 | 2330 ± 252.3 |
| Cycle 1 Day 15 (3 hours) | 5390 ± 106.9 | 4120 ± 92.0 |
| Cycle 1 Day 15 (4 hours) | 3130 ± 114.6 | 3130 ± 95.2 |
| Cycle 1 Day 15 (6 hours) | 2830 ± 112.6 | 2670 ± 97.3 |
| Cycle 1 Day 15 (8 hours) | 4410 ± 74.8 | 2630 ± 133.1 |
| Cycle 1 Day 15 (12 hours) | 4290 ± 53.4 | 2600 ± 164.4 |
| Cycle 3 Day 1 (predose/0hour) | 1110 ± 42.4 | 949 ± 142.6 |
| Cycle 5 Day 1 (predose/0hour) | 650 ± 42.9 | 1050 ± 174.6 |
| Cycle 7 Day 1 (predose/0hour) | 1530 ± 60.9 | 1150 ± 181.6 |
JDQ443 concentration data of non-Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.
| ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| Cycle 1 Day 1 (predose/0hour) | 0 ± 0 | 0 ± 0 |
| Cycle 1 Day 1 (4 hours) | 3140 ± 85.5 | 5760 ± 34.9 |
| Cycle 1 Day 1 (6 hours) | 2940 ± 69.8 | 4840 ± 49.9 |
| Cycle 1 Day 15 (predose/0hour) | 1570 ± 98.1 | 1510 ± 97.5 |
| Cycle 1 Day 15 (1 hour) | 2400 ± 103.1 | 4480 ± 23.1 |
| Cycle 1 Day 15 (2 hours) | 3270 ± 87.4 | 5930 ± 23.8 |
| Cycle 1 Day 15 (3 hours) | 3500 ± 67.2 | 6120 ± 23.9 |
| Cycle 1 Day 15 (4 hours) | 3300 ± 55.9 | 4910 ± 31.2 |
| Cycle 1 Day 15 (6 hours) | 2810 ± 66.2 | 4010 ± 43.4 |
| Cycle 1 Day 15 (8 hours) | 1950 ± 89.4 | 3300 ± 41.00 |
| Cycle 1 Day 15 (12 hours) | 1460 ± 116.0 | 2320 ± 62.3 |
| Cycle 3 Day 1 (predose/0hour) | 1050 ± 175.9 | 1180 ± 217.6 |
| Cycle 5 Day 1 (predose/0hour) | 1030 ± 74.7 | 1550 ± 90.5 |
| Cycle 7 Day 1 (predose/0hour) | 917 ± 74.4 | 1500 ± 85.1 |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Cmax was listed and summarized using descriptive statistics.
| ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 4170 ± 59.8 | 5160 ± 52.4 |
| Chinese participants | 6010 ± 82.5 | 4320 ± 103.0 |
| non-Chinese participants | 3920 ± 57.5 | 5430 ± 45.7 |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tmax was listed and summarized using descriptive statistics.
| Hours | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 2.96 (0.967 to 9.50) | 3.00 (1.00 to 10.8) |
| Chinese participants | 3.58 (3.05 to 4.10) | 3.61 (3.13 to 4.08) |
| non-Chinese participants | 2.61 (0.967 to 9.50) | 2.98 (1.00 to 10.8) |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tlast was listed and summarized using descriptive statistics.
| Hours | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 10.1 (6.00 to 16.9) | 11.1 (10.0 to 21.0) |
| Chinese participants | 11.9 (11.6 to 12.2) | 11.2 (11.1 to 11.4) |
| non-Chinese participants | 10.1 (6.00 to 16.9) | 11.0 (10.0 to 21.0) |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUC∞ was listed and summarized using descriptive statistics.
| hr*ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 33400 ± 69.0 | 41800 ± 21.7 |
| non-Chinese participants | 33400 ± 69.0 | 41800 ± 21.7 |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUClast was listed and summarized using descriptive statistics.
| hr*ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 29100 ± 79.3 | 44200 ± 47.6 |
| Chinese participants | 52700 ± 84.7 | 33500 ± 137.2 |
| non-Chinese participants | 26400 ± 75.7 | 47900 ± 25.5 |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUCτ was listed and summarized using descriptive statistics.
| hr*ng/mL | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 34500 ± 69.4 | 42700 ± 50.6 |
| Chinese participants | 53500 ± 79.2 | 35400 ± 135.1 |
| non-Chinese participants | 31600 ± 67.4 | 45100 ± 35.0 |
Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. CL/F was listed and summarized using descriptive statistics.
| mL/hr | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| All participants | 5800 ± 69.4 | 4680 ± 50.6 |
| Chinese participants | 3730 ± 79.2 | 5650 ± 135.1 |
| non-Chinese participants | 6340 ± 67.4 | 4440 ± 35.0 |
Collected over From first dose of study treatment up to the cut-off date for the primary analysis (04-Nov-2024), approximately 22 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A- PD-L1<1% | 15/72 (20.8%) | 29/72 (40.3%) | 60/72 (83.3%) |
| Cohort B- PD-L1≥ 1% and STK11 Mutation | 4/23 (17.4%) | 10/23 (43.5%) | 21/23 (91.3%) |
| Event | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| PneumoniaInfections and infestations | 5/72 | 2/23 |
| SepsisInfections and infestations | 1/72 | 2/23 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/72 | 2/23 |
| Pericardial effusionCardiac disorders | 2/72 | 1/23 |
| DiarrhoeaGastrointestinal disorders | 0/72 | 1/23 |
| PyrexiaGeneral disorders and administration site conditions | 0/72 | 1/23 |
| Hepatic cytolysisHepatobiliary disorders | 0/72 | 1/23 |
| Neck painMusculoskeletal and connective tissue disorders | 0/72 | 1/23 |
| Acute kidney injuryRenal and urinary disorders | 0/72 | 1/23 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/72 | 1/23 |
| Event | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 21/72 | 4/23 |
| DiarrhoeaGastrointestinal disorders | 19/72 | 1/23 |
| ConstipationGastrointestinal disorders | 12/72 | 6/23 |
| NauseaGastrointestinal disorders | 18/72 | 5/23 |
| Oedema peripheralGeneral disorders and administration site conditions | 13/72 | 5/23 |
| Weight decreasedInvestigations | 8/72 | 5/23 |
| AstheniaGeneral disorders and administration site conditions | 14/72 | 3/23 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/72 | 2/23 |
| FatigueGeneral disorders and administration site conditions | 13/72 | 4/23 |
| Alanine aminotransferase increasedInvestigations | 5/72 | 4/23 |
| Age, Continuous(Years) | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation | Total |
|---|---|---|---|
| Mean | 67.7 ± 7.68 | 63.7 ± 10.29 | 66.7 ± 8.50 |
| Sex: Female, Male(Participants) | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation | Total |
|---|---|---|---|
| Female | 25 | 5 | 30 |
| Male | 47 | 18 | 65 |
| Race/Ethnicity, Customized(Participants) | Cohort A- PD-L1<1% | Cohort B- PD-L1≥ 1% and STK11 Mutation | Total |
|---|---|---|---|
| White | 57 | 13 | 70 |
| Asian | 11 | 7 | 18 |
| Unknown | 4 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2022 to primary completion in Nov 2024, 22 months.
Results were first posted in Oct 2025, 11 months after primary completion.
Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 22 months is below that.
Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JDQ443